EGFR and non-small cell lung carcinoma: According to the study by Li T et al., EGFR-mutant NSCLC exhibit lower TMB (mean ~3.9 vs. ~6.1 mutations/Mb in KRAS, p < 0.001), resulting in fewer neoantigens to be available to APC to prime T cells.